Endothelin Receptor

亜型選択性的な製品

ET-A ET-B

シグナル伝達経路

Endothelin Receptor製品

All (8)
Endothelin Receptor拮抗剤(8)
新製品

製品コード	製品名称	製品説明	文献中Selleckの製品使用例	お客様のフィードバック
S3051	Bosentan Hydrate	Bosentan (Ro 47-0203) is an endothelin (ET) receptor antagonist for ET-A and ET-B with K_i of 4.7 nM and 95 nM, respectively.	J Immunother Cancer, 2024, 12(11)e009805 Transl Oncol, 2024, 44:101944 Ann Dermatol, 2024, 36(3):151-162
S8051	Macitentan	Macitentan is an orally active, non-peptide, dual ETA/ETB (endothelin) receptor antagonist with IC50 of 0.5 nM/391 nM.	J Immunother Cancer, 2024, 12(11)e009805 Biomedicines, 2022, 10(3)629 Front Pharmacol, 2021, 12:740529
S7883	BQ-123	BQ-123 is a selective endothelin A receptor (ETA) antagonist with IC50 of 7.3 nM. Phase 2.	Baghdad Sci J, 2023, 2023, 20(5 Suppl.) Baghdad Science Journal, 2023, 20(5 Suppl.) J Mol Cell Cardiol, 2022, 171:16-29
S1456	Zibotentan (ZD4054)	Zibotentan (ZD4054) is a specific Endothelin (ET)A antagonist with IC50 of 21 nM, exhibiting no activity at ETB. Phase 3.	Cell Death Dis, 2023, 14(1):5 Hepatology, 2016, 63(3):1000-12 Oncotarget, 2016, 7(47):77138-77151
S2097	Ambrisentan	Ambrisentan (LU-208075, BSF-208075) is a highly selective antagonist of the endothelin-1 type A receptor, used in the treatment of pulmonary arterial hypertension (PAH).	Eur J Pharmacol, 2019, 855:124-136 Pharmacol Res Perspect, 2017, 5(6)
S4220^New	Bosentan	Bosentan is an endothelin (ET) receptor antagonist for ET-A and ET-B with K_i of 4.7 nM and 95 nM, respectively.	Oncotarget, 2016, 7(20):29187-98 PLoS One, 2016, 11(9):e0161988
S6665	Sparsentan (PS-433540, RE-021)	Sparsentan (PS-433540, RE-021, DARA) is a dual endothelin type A receptor(ETA) and angiotensin II type 1 receptor antagonist.	Front Pharmacol, 2022, 13:964370 Biomedicines, 2021, 10(1)86
S0017	Lu-135252	Lu-135252 (Darusentan,HMR-4005) is a selective endothelin A receptor (ET-A receptor) antagonist indicated for the oral treatment of resistant hypertension.
S3051	Bosentan Hydrate	Bosentan (Ro 47-0203) is an endothelin (ET) receptor antagonist for ET-A and ET-B with K_i of 4.7 nM and 95 nM, respectively.	J Immunother Cancer, 2024, 12(11)e009805 Transl Oncol, 2024, 44:101944 Ann Dermatol, 2024, 36(3):151-162
S8051	Macitentan	Macitentan is an orally active, non-peptide, dual ETA/ETB (endothelin) receptor antagonist with IC50 of 0.5 nM/391 nM.	J Immunother Cancer, 2024, 12(11)e009805 Biomedicines, 2022, 10(3)629 Front Pharmacol, 2021, 12:740529
S7883	BQ-123	BQ-123 is a selective endothelin A receptor (ETA) antagonist with IC50 of 7.3 nM. Phase 2.	Baghdad Sci J, 2023, 2023, 20(5 Suppl.) Baghdad Science Journal, 2023, 20(5 Suppl.) J Mol Cell Cardiol, 2022, 171:16-29
S1456	Zibotentan (ZD4054)	Zibotentan (ZD4054) is a specific Endothelin (ET)A antagonist with IC50 of 21 nM, exhibiting no activity at ETB. Phase 3.	Cell Death Dis, 2023, 14(1):5 Hepatology, 2016, 63(3):1000-12 Oncotarget, 2016, 7(47):77138-77151
S2097	Ambrisentan	Ambrisentan (LU-208075, BSF-208075) is a highly selective antagonist of the endothelin-1 type A receptor, used in the treatment of pulmonary arterial hypertension (PAH).	Eur J Pharmacol, 2019, 855:124-136 Pharmacol Res Perspect, 2017, 5(6)
S4220^New	Bosentan	Bosentan is an endothelin (ET) receptor antagonist for ET-A and ET-B with K_i of 4.7 nM and 95 nM, respectively.	Oncotarget, 2016, 7(20):29187-98 PLoS One, 2016, 11(9):e0161988
S6665	Sparsentan (PS-433540, RE-021)	Sparsentan (PS-433540, RE-021, DARA) is a dual endothelin type A receptor(ETA) and angiotensin II type 1 receptor antagonist.	Front Pharmacol, 2022, 13:964370 Biomedicines, 2021, 10(1)86
S0017	Lu-135252	Lu-135252 (Darusentan,HMR-4005) is a selective endothelin A receptor (ET-A receptor) antagonist indicated for the oral treatment of resistant hypertension.
S4220^New	Bosentan	Bosentan is an endothelin (ET) receptor antagonist for ET-A and ET-B with K_i of 4.7 nM and 95 nM, respectively.	Oncotarget, 2016, 7(20):29187-98 PLoS One, 2016, 11(9):e0161988

Endothelin Receptor阻害剤の選択性比較

Tags: Endothelin Receptor inhibitor|Endothelin Receptor agonist|Endothelin Receptor activator|Endothelin Receptor inducer|Endothelin Receptor antagonist|Endothelin Receptor signaling pathway|Endothelin Receptor assay kit